Viekira Pak & Technivie Lawsuit Attorney
Did you sustain liver injuries? You may have a lawsuit! (713) 621-7944
The attorneys at Fleming | Nolen | Jez, L.L.P. are currently investigating claims that allege Viekira Pak and Technivie can cause serious liver damage. Viekira Pak and Technivie are prescribed to some people to treat hepatitis C, but last October, the FDA issued a warning that these drugs have been linked to liver injuries in patients with a history of liver disease. Some Viekira Pak and Technivie patients say that their use of the drug resulted in the need for a liver transplant, and some died.
We are offering free consultations to patients and families of patients who sustained liver injuries after taking Viekira Pak or Technivie. Find out if you have a claim!
On December 19, 2014, the FDA approved Viekira Pak based on incomplete studies it would cure 90% of those taking this drug from Hepatitis. Less than a year later on October 22, 2015, the FDA issued a significant warning about Viekira Pak & Technivie stating that these drugs can result in significant liver damage, particularly in patients with existing advanced liver conditions. AbbVie Pharmaceuticals, has changed their label to reflect the new warning.
What is Viekira Pak & Technivie used for?
Viekira Pak and Technivie are antiviral medicines that reduce the amount of hepatitis C virus in the body by preventing the virus from multiplying and may slow down the disease. Viekira Pak is FDA-approved for use in patients with genotype 1 chronic hepatitis C infection including those with compensated cirrhosis.
Viekira Pak is a Hepatitis drug that is a fixed-dose combination antiviral pill used with or without Ribavirin, containing 4 drugs: